Report Summary
Eternity Insights can provide a deep dive research report highlighting the market and competitive in-telligence across the key segments of the market. The report also considers the impact of COVID-19 on the global Oncology Biosimilars market. The report considers 2018-2020 historic period, 2021 as base year, and 2022-2028 as forecast period. The report includes quantitative analysis of the market supported by the mar-ket drivers, challenges, and trends to accurately map the market scenario and competition.
Oncology Biosimilars market report is based on robust research methodology designed using blend of research ap-proaches developed using secondary/desk research and validated through the primary research and expert insights. Eternity Insights also uses paid data bases such as FACIVA, Hoovers, and other bench-marking and forecasting tools to provide accurate statistical analysis of supply and demand trends.
To learn more about this report
Key Research Highlights: Market Drivers
The Oncology Biosimilars market is estimated to expand at a considerable growth rate during the forecast period ow-ing to increasing prevalence of venous diseases and increasing new product approvals to cater this demand. Rise in the awareness about the diseases, increasing importance of early diagnosis, and growing spending on chronic diseases are poised to boost the market growth. Moreover, the key players in the market are investing in research and development of technologically advanced products leading to increased utilization of the Oncology Biosimilars products across developed and developing countries of the world.
Key Research Highlights: Market Restrains
Limited awareness about the diseases, high cost of products, low economical condition, and lack of favorable insurance systems restricts the adoption of Oncology Biosimilars products across developing regions of the globe. However, launch of new products with low cost and increasing efforts for market penetration in these regions can offer lucrative growth opportunities for the players in the Oncology Biosimilars market.
To learn more about this report
Key Research Highlights: Trends
Increasing research and development spending on Oncology Biosimilars development has been the leading industry trend of Oncology Biosimilars market
The leading players in the market are focused on developing products which are cost effective and high quality to tap the huge unaddressed opportunities in the developing regions. This can be wit-nessed from the increasing spending on research and development and growing number of new product approvals.
Global Oncology Biosimilars Market Size, 2018-2028 (USD MILLION)
To learn more about this report
Market Segmentation
| Report Attributes |
Details |
| The market size value in 2021 |
USD XX.XX Million |
| CAGR (2021 - 2028) |
XX.XX % |
| The Revenue forecast in 2028 |
USD XX.XX Million |
| Base year for estimation |
2021 |
| Historical data |
2018-2019 |
| Forecast period |
2022-2028 |
| Quantitative units |
- Revenue in USD Million
- CAGR from 2021 to 2028
|
| Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments covered |
By Type Outlook, Application Outlook, Regional Outlook |
| By Type Outlook |
mAb,Immunomodulators,Hematopoietic Agents,G-CSF ,Others |
| By Application Outlook |
Retail Pharmacies,Hospital Pharmacy,Online Pharmacy, Other |
| Regional scope |
North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Country scope |
U.S., Canada, U.K., Germany, France, BENELUX, China, India, Japan, South Korea, Brazil, Saudi Arabia, UAE, Turkey |
| Key companies profiled |
Celltrion,Biocon,Dr. Reddy�s Laboratories,STADA Arzneimittel AG,Intas Pharmaceuticals,Pfizer,Sandoz International,Teva Pharmaceutical Industries Ltd,Apotex,BIOCAD |
| Customization Available |
Yes, the report can be tailored to meet your specific requirements. |
Key Market Players
- Celltrion
- Biocon
- Dr. Reddy�s Laboratories
- STADA Arzneimittel AG
- Intas Pharmaceuticals
- Pfizer
- Sandoz International
- Teva Pharmaceutical Industries Ltd
- Apotex
- BIOCAD
Oncology Biosimilars Market, By Type
- mAb
- Immunomodulators
- Hematopoietic Agents
- G-CSF
- Others
Oncology Biosimilars Market, By Application
- Retail Pharmacies
- Hospital Pharmacy
- Online Pharmacy
- Other
Key Benefits To The Stake Holders
- Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors
- Provision of market value (USD Billion) and volume (Tons) data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry with respect to recent developments (which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Table Of Contents
Table of Contents
1 Report Overview
1.1 Study Scope
1.2 Major Manufacturers Covered in This Report
1.3 Market Segment by Type
1.3.1 Global Oncology Biosimilars Market Size Growth Rate by Type (2019-2025)
1.3.2 mAb
1.3.3 Immunomodulators
1.3.4 Hematopoietic Agents
1.3.5 G-CSF
1.3.6 Others
1.4 Market Segment by Application
1.4.1 Global Oncology Biosimilars Market Share by Application (2019-2025)
1.4.2 Retail Pharmacies
1.4.3 Hospital Pharmacy
1.4.4 Online Pharmacy
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Oncology Biosimilars Market Size
2.1.1 Global Oncology Biosimilars Revenue 2014-2025
2.1.2 Global Oncology Biosimilars Sales 2014-2025
2.2 Oncology Biosimilars Growth Rate by Regions
2.2.1 Global Oncology Biosimilars Sales by Regions 2014-2019
2.2.2 Global Oncology Biosimilars Revenue by Regions 2014-2019
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
3 Market Share by Manufacturers
3.1 Oncology Biosimilars Sales by Manufacturers
3.1.1 Oncology Biosimilars Sales by Manufacturers 2014-2019
3.1.2 Oncology Biosimilars Sales Market Share by Manufacturers 2014-2019
3.2 Revenue by Manufacturers
3.2.1 Oncology Biosimilars Revenue by Manufacturers (2014-2019)
3.2.2 Oncology Biosimilars Revenue Share by Manufacturers (2014-2019)
3.2.3 Global Oncology Biosimilars Market Concentration Ratio (CR5 and HHI)
3.3 Oncology Biosimilars Price by Manufacturers
3.4 Key Manufacturers Oncology Biosimilars Plants/Factories Distribution and Area Served
3.5 Date of Key Manufacturers Enter into Oncology Biosimilars Market
3.6 Key Manufacturers Oncology Biosimilars Product Offered
3.7 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Sales and Revenue for Each Type
4.1.1 mAb Sales and Revenue (2014-2019)
4.1.2 Immunomodulators Sales and Revenue (2014-2019)
4.1.3 Hematopoietic Agents Sales and Revenue (2014-2019)
4.1.4 G-CSF Sales and Revenue (2014-2019)
4.1.5 Others Sales and Revenue (2014-2019)
4.2 Global Oncology Biosimilars Sales Market Share by Type
4.3 Global Oncology Biosimilars Revenue Market Share by Type
4.4 Oncology Biosimilars Price by Type
5 Market Size by Application
5.1 Overview
5.2 Global Oncology Biosimilars Sales by Application
6 United States
6.1 United States Oncology Biosimilars Breakdown Data by Company
6.2 United States Oncology Biosimilars Breakdown Data by Type
6.3 United States Oncology Biosimilars Breakdown Data by Application
7 European Union
7.1 European Union Oncology Biosimilars Breakdown Data by Company
7.2 European Union Oncology Biosimilars Breakdown Data by Type
7.3 European Union Oncology Biosimilars Breakdown Data by Application
8 China
8.1 China Oncology Biosimilars Breakdown Data by Company
8.2 China Oncology Biosimilars Breakdown Data by Type
8.3 China Oncology Biosimilars Breakdown Data by Application
9 Rest of World
9.1 Rest of World Oncology Biosimilars Breakdown Data by Company
9.2 Rest of World Oncology Biosimilars Breakdown Data by Type
9.3 Rest of World Oncology Biosimilars Breakdown Data by Application
9.4 Rest of World Oncology Biosimilars Breakdown Data by Countries
9.4.1 Rest of World Oncology Biosimilars Sales by Countries
9.4.2 Rest of World Oncology Biosimilars Revenue by Countries
9.4.3 Japan
9.4.4 Korea
9.4.5 India
9.4.6 Southeast Asia
10 Company Profiles
10.1 Celltrion
10.1.1 Celltrion Company Details
10.1.2 Company Description and Business Overview
10.1.3 Sales, Revenue and Market Share of Oncology Biosimilars
10.1.4 Oncology Biosimilars Product Introduction
10.1.5 Celltrion Recent Development
10.2 Biocon
10.2.1 Biocon Company Details
10.2.2 Company Description and Business Overview
10.2.3 Sales, Revenue and Market Share of Oncology Biosimilars
10.2.4 Oncology Biosimilars Product Introduction
10.2.5 Biocon Recent Development
10.3 Dr. Reddy’s Laboratories
10.3.1 Dr. Reddy’s Laboratories Company Details
10.3.2 Company Description and Business Overview
10.3.3 Sales, Revenue and Market Share of Oncology Biosimilars
10.3.4 Oncology Biosimilars Product Introduction
10.3.5 Dr. Reddy’s Laboratories Recent Development
10.4 STADA Arzneimittel AG
10.4.1 STADA Arzneimittel AG Company Details
10.4.2 Company Description and Business Overview
10.4.3 Sales, Revenue and Market Share of Oncology Biosimilars
10.4.4 Oncology Biosimilars Product Introduction
10.4.5 STADA Arzneimittel AG Recent Development
10.5 Intas Pharmaceuticals
10.5.1 Intas Pharmaceuticals Company Details
10.5.2 Company Description and Business Overview
10.5.3 Sales, Revenue and Market Share of Oncology Biosimilars
10.5.4 Oncology Biosimilars Product Introduction
10.5.5 Intas Pharmaceuticals Recent Development
10.6 Pfizer
10.6.1 Pfizer Company Details
10.6.2 Company Description and Business Overview
10.6.3 Sales, Revenue and Market Share of Oncology Biosimilars
10.6.4 Oncology Biosimilars Product Introduction
10.6.5 Pfizer Recent Development
10.7 Sandoz International
10.7.1 Sandoz International Company Details
10.7.2 Company Description and Business Overview
10.7.3 Sales, Revenue and Market Share of Oncology Biosimilars
10.7.4 Oncology Biosimilars Product Introduction
10.7.5 Sandoz International Recent Development
10.8 Teva Pharmaceutical Industries Ltd
10.8.1 Teva Pharmaceutical Industries Ltd Company Details
10.8.2 Company Description and Business Overview
10.8.3 Sales, Revenue and Market Share of Oncology Biosimilars
10.8.4 Oncology Biosimilars Product Introduction
10.8.5 Teva Pharmaceutical Industries Ltd Recent Development
10.9 Apotex
10.9.1 Apotex Company Details
10.9.2 Company Description and Business Overview
10.9.3 Sales, Revenue and Market Share of Oncology Biosimilars
10.9.4 Oncology Biosimilars Product Introduction
10.9.5 Apotex Recent Development
10.10 BIOCAD
10.10.1 BIOCAD Company Details
10.10.2 Company Description and Business Overview
10.10.3 Sales, Revenue and Market Share of Oncology Biosimilars
10.10.4 Oncology Biosimilars Product Introduction
10.10.5 BIOCAD Recent Development
11 Value Chain and Sales Channels Analysis
11.1 Value Chain Analysis
11.2 Sales Channels Analysis
11.2.1 Oncology Biosimilars Sales Channels
11.2.2 Oncology Biosimilars Distributors
11.3 Oncology Biosimilars Customers
12 Market Forecast
12.1 Global Oncology Biosimilars Sales and Revenue Forecast 2019-2025
12.2 Global Oncology Biosimilars Sales Forecast by Type
12.3 Global Oncology Biosimilars Sales Forecast by Application
12.4 Oncology Biosimilars Forecast by Regions
12.4.1 Global Oncology Biosimilars Sales Forecast by Regions 2019-2025
12.4.2 Global Oncology Biosimilars Revenue Forecast by Regions 2019-2025
12.5 United States Market Forecast
12.6 European Union Market Forecast
12.7 China Market Forecast
12.8 Rest of World
12.8.1 Japan
12.8.2 Korea
12.8.3 India
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.1.1 Research Programs/Design
14.1.1.2 Market Size Estimation
14.1.1.3 Market Breakdown and Data Triangulation
14.1.2 Data Source
14.1.2.1 Secondary Sources
14.1.2.2 Primary Sources
14.2 Author Details
14.3 Disclaimer
